###begin article-title 0
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 479 483 479 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 622 626 622 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 785 789 785 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 1145 1149 1145 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
###xml 525 533 <span type="species:ncbi:9606">patients</span>
Tau aggregation is one of the major features in Alzheimer's disease and in several other tauopathies, including frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), and progressive supranuclear palsy (PSP). More than 35 mutations in the tau gene have been identified from FTDP-17 patients. A group of these mutations alters splicing of exon 10, resulting in an increase in exon 10 inclusion into tau mRNA. Abnormal splicing with inclusion of exon 10 into tau mRNA has also been observed in PSP and AD patients. These results indicate that abnormal splicing of exon 10, leading to the production of tau with exon 10, is probably one of the mechanisms by which tau accumulates and aggregates in tauopathic brains. Therefore, modulation of exon 10 splicing in the tau gene could potentially be targeted to prevent tauopathies. To identify small molecules or compounds that could potentially be developed into drugs to treat tauopathies, we established a cell-based high-throughput screening assay. In this review, we will discuss how realistic, specific biological molecules can be found to regulate exon 10 splicing in the tau gene for potential treatment of tauopathies.
###end p 2
###begin title 3
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
Alternative splicing of exon 10 in the tau gene
###end title 3
###begin p 4
###xml 628 629 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 630 631 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 750 751 750 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 864 865 864 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 866 867 866 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 883 886 883 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 1139 1141 1139 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1142 1144 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1344 1346 1344 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 501 506 <span type="species:ncbi:9606">human</span>
Splicing of pre-mRNA is a complicated process that is regulated by intron and exon sequences, SR (serine/arginine-rich) proteins, and other non-SR splicing factors, for example, heterogeneous nuclear ribonucleoproteins (hnRNPs). Alternative splicing occurs when the introns of a certain pre-mRNA are excised in more than one way, producing structurally and functionally different proteins from the same gene in different cells, or different developmental stages. It is estimated that more than 60% of human genes undergo alternative splicing, making the cellular process an essential mechanism for generating protein diversity [1-4]. Both constitutive and alternative splicing play important roles in the regulation of gene expression in eukaryotes [5]. A growing number of genetic diseases have been found to be caused by alternative or aberrant splicing events [6-9]. Mutations in cis-elements for splicing are primarily responsible for these diseases. However, tissue-specific splicing factors, such as those identified in amyotrophic lateral sclerosis (ALS), are also suggested to cause the aberrant pathogenic processing of pre-mRNA [10-13]. In addition, polymorphisms and genetic background contribute to variation in alternative splicing in specific genes, leading to modification of phenotypes in diseases (reviewed by Wang and Cooper [14]).
###end p 4
###begin p 5
###xml 163 166 163 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 766 768 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 973 975 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1173 1176 1173 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 1330 1332 1330 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1333 1335 1333 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
A typical exon is defined by its sequence, which is usually less than 300 base pairs long and, together with its surrounding introns, contains at least three core cis-elements: a 5' splicing site, a 3' splicing site, and a branch point [5,15]. The splicing events begin with recognition of these elements by assembly of the spliceosome, a complex consisting of different small nuclear ribonuclear particles (snRNPs; U1, U2AF65, U4/U6, and U5), SR proteins (SRP30C, SRP20, SRP40, SRP55, SC35, SF2, hTra2b1), and other factors, including SF1 [5] (reviewed by Kramer [15]). The 5' site is initially paired with U1 snRNP and then replaced by U6 snRNP. The large subunit of splicing factor U2AF binds to the polypyrimidine tract while SF1 interacts with the branch site [16]. SR proteins, on the other hand, function as trans-splicing factors that facilitate the interaction of U1 snRNP with the 5' splice site, and the assembly of spliceosomes. through interactions with U2AF [17], SF1, and other splicing factors. After a series of conformational changes, introns are enzymatically removed and exons are ligated at 5' and 3' splicing sites. Exons, as well as introns, contain cis-regulatory splicing elements that activate or inhibit the splicing of a specific exon. These elements include splicing enhancers and splicing silencers [18-21]. Due to the involvement of many factors in the process of alternative splicing, one would expect that any change of these elements in the overall equation would tip the balance of exon inclusion/exclusion.
###end p 5
###begin p 6
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1029 1030 1029 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1033 1035 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 232 237 <span type="species:ncbi:9606">human</span>
The human tau gene is more than 100 kilobases long and has been mapped to chromosome 17q21. It contains 16 exons, with the first exon (-1) as a part of the promoter (Figure 1). Exons 4A, 6, and 8 are not present in the tau mRNAs in human brain [22]. A full-length tau protein is encoded by exons 1-13 and consists of 441 amino acids. Three exons (exons 2, 3, and 10) undergo alternative splicing, giving rise to six isoforms of tau (Figure 1). The fetal tau isoform excludes exons 2, 3, and 10, while adults express all six tau isoforms, which range from 352-441 amino acids in length, depending on inclusion or exclusion of exons 2, 3, and 10 [23]. One of the major characteristics of the tau protein is the presence of four carboxy-terminal tandem repeat sequences (of 31 or 32 amino acids), each of which is encoded by exons 9, 10, 11, and 12 [24-27]. Since exon 10, which encodes the second repeat, is alternatively spliced., isoforms of tau are classified as either 3R taus (three repeats) or 4R taus (four repeats) (Figure 1) [28].
###end p 6
###begin p 7
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 120 125 <span type="species:ncbi:9606">human</span>
The tau genomic structure and splicing products. The tau gene has 16 exons. Exons 4A, 6, and 8 are not expressed in the human brain. Exons 2, 3, and 10 are alternatively spliced, producing six different mRNAs. The mRNA with or without exon 10 encodes a tau protein with four repeats (4R) or three repeats (3R), respectively. Adapted from Lee et al. [28].
###end p 7
###begin p 8
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 475 479 475 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 531 534 531 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 688 690 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 691 693 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 694 696 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 710 714 707 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 840 842 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 843 845 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 846 848 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 992 994 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 995 997 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1033 1036 1027 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 1050 1055 1044 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
Alternative splicing of exon 10 is developmentally regulated. It has been shown that >95% of tau mRNA in fetal brain excludes exon 10, while 40-50% of tau mRNAs in adult central nervous system includes this exon [29]. Exon 10 is relatively small at 93 base pairs. Exonic splicing enhancers, as well as an exonic splicing silencer, have been identified within this exon [29-31]. By analyzing mini-genes constructed from exon 9, intron 9, exon 10, intron 10 and exon 11 of the tau gene, we and others have also shown that additional cis-elements, including exon 9, exon 11, and trans-factors - for example, SRp20, SRp55, SRp75, SRp30c, ASF, SC35 and hTra2beta1 - regulate exon 10 splicing [29,32-34]. Studies of tau pre-mRNA identified a stem-loop structure at the exon 10-intron 10 boundary, the disruption of which alters exon 10 splicing [30,35,36]. Several splicing factors, including hTra2beta1, SF2/ASF, SRp55, and SRp30C, affect exon 10 splicing by directly binding to exonic enhancers [37,38]. However, it is unclear how other cis-elements and trans-factors are involved in exon 10 splicing.
###end p 8
###begin p 9
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 870 872 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 907 912 <span type="species:ncbi:9606">human</span>
Tau is abundantly expressed in the central nervous system, predominantly located in axons, and expression is also detectable in the axons of peripheral neurons. Only low levels of expression are observed in central nervous system astrocytes and oligodendrocytes [39-41]. The main function of tau is to bind and stabilize microtubules. The binding of tau to microtubules promotes their polymerization [39,42]. Analysis of the tau sequence revealed that tau has four microtubule-binding motifs that are located in four repeat regions at the carboxyl terminus of the protein within conserved 18 residue long binding elements separated by less conserved spacers of 13-14 amino acids [28]. 4R-tau isoforms, which contain an additional binding element, have a greater affinity for microtubules and are more efficient in promoting their polymerization than 3R-tau isoforms [43,44]. It is interesting that in adult human brain, the ratio of 3R-tau to 4R-tau isoforms is about 1 [43]. Therefore, one would expect that in a normal individual the ratio of 4R-tau/3R-tau proteins is balanced.
###end p 9
###begin title 10
###xml 29 32 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tau</italic>
Tauopathies and mutations in Tau
###end title 10
###begin p 11
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 581 585 581 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 750 754 750 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 771 773 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 774 776 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 826 830 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 861 863 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 927 931 927 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 1009 1011 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1083 1084 1083 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1089 1091 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1201 1202 1201 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1207 1209 1207 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 1210 1212 1210 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1318 1322 1318 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 1437 1439 1437 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1440 1442 1440 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1443 1445 1443 1445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 1446 1448 1446 1448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1449 1451 1449 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1672 1675 1672 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 1692 1693 1692 1693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1747 1751 1747 1751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 1838 1840 1838 1840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1841 1843 1841 1843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1844 1846 1844 1846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 2052 2056 2048 2052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 2112 2114 2108 2110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 2115 2117 2111 2113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 848 856 <span type="species:ncbi:9606">patients</span>
Tauopathies comprise a group of neurodegenerative disorders that share a common pathological feature: the formation of insoluble intraneuronal aggregates composed of filamentous hyperphosphorylated tau proteins [28,45]. Paired helical filaments and the hyperphosphorylation of tau are two of the most recognized molecular characteristics in Alzheimer's disease (AD) and several other neurodegenerative tauopathies, for example, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) and progressive supranuclear palsy (PSP) [28]. The genetic relevance between tau and tauopathies came from linkage analysis of FTDP-17 and other neurodegenerative diseases, many of which were mapped to the region on chromosome 17q21-22 where the tau gene is located [46-50]. Subsequently, mutations were identified in the tau gene from FTDP-17 patients [48,51-53]. To date, at least 35 distinct pathogenic mutations in the tau gene that lead to the formation of filaments made of hyperphosphorylated tau [54] have been described in a large number of families with FTDP-17 (Table 1; ) [22,55]. Several other mutations have also been described in PSP, Pick's disease, and Parkinson's disease (Table 2; ) [56-60]. It has also been demonstrated that the majority of missense mutations that reside in coding regions of tau exons 9, 10, 12, or 13 alter the ability of tau to interact with microtubules and to promote microtubule assembly [51,52,59,61-63]. On the other hand, additional mutations (for example, three silent mutations in exon 10, a deletion mutation, seven substitutions of the intron following exon 10, and one mutation in intron 9) disrupt exon 10 splicing cis-elements (Table 1). This mostly results in the increased production of tau mRNA with exon 10 inclusion, shifting the 3R-tau/4R-tau ratio in favor of more 4R-tau [51,64-66]. It has been also demonstrated that the exonic mutations S305N, N279K, Delta280K, and N296H may not only alter tau functions, but also affect splicing enhancers, or destabilize the stem loop structure of tau pre-mRNA, causing abnormal exon 10 inclusion/exclusion [30,67]. All these results suggest that aberrant exon 10 splicing is one of the most important mechanisms in the pathogenesis of tauopathies.
###end p 11
###begin p 12
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Mutations in the tau gene that are identified in FTDP-17 patients
###end p 12
###begin p 13
Data are derived from . Mutations in bold affect exon 10 splicing. IVS, intervening sequence.
###end p 13
###begin p 14
Mutations in the tau gene that are identified in other tauopathies
###end p 14
###begin p 15
Data are derived from . PSP, progressive supranuclear palsy.
###end p 15
###begin p 16
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 563 567 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 885 889 885 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 966 973 966 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1456 1460 1456 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 1631 1633 1631 1633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 1634 1636 1634 1636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 1637 1639 1637 1639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
###xml 1099 1107 <span type="species:ncbi:9606">patients</span>
###xml 1472 1480 <span type="species:ncbi:9606">patients</span>
###xml 1621 1629 <span type="species:ncbi:9606">patients</span>
In addition to the mutations that have been identified in FTDP-17 patients, it has been suggested that additional pathogenic mutations or polymorphisms in introns that affect exon 10 splicing may be present in tauopathies [28]. Analysis of tau protein and mRNA in PSP indicates that more 4R-tau is produced in these patients [68]. However, unlike other tauopathies, PSP has usually been considered to be sporadic in nature. Conrad et al. [69], however, demonstrated an association between a polymorphic dinucleotide repeat marker, (GT)n, found in intron 9 of the tau gene and PSP. These results were subsequently confirmed by several other groups [70,71]. Further studies indicate that a series of polymorphisms within the tau gene (for example, eight single nucleotide polymorphisms, one deletion, and the (TG)n repeat) are inherited in completed linkage disequilibrium, defining the tau gene as two extended haplotypes, H1 and H2 [72] (reviewed by Schraen-Maschke et al. [22]). Importantly, it was found that the most common allele (H1 haplotype) and genotype (H1/H1) were over-represented in PSP patients compared with normal controls. However, although the dinucleotide polymorphism is associated with extended H1/H2 haplotypes in disequilibrium, it has been considered a variation that may not have biological significance in the disease process. Taken together with the discoveries of the over-production of 4R-tau, and disequilibrium linkage to the tau gene in PSP patients, it is reasonable to presume that variations in intron 9 or intron 10 could be critical to influencing exon 10 inclusion/exclusion in these patients [71,73-75].
###end p 16
###begin p 17
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 283 288 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 553 557 553 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 585 589 585 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 637 641 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 575 583 <span type="species:ncbi:9606">patients</span>
###xml 760 768 <span type="species:ncbi:9606">patients</span>
In contrast, dysregulation of tau pre-mRNA splicing contributing to AD pathogenesis is still under debate. Several groups have shown by quantitative RT-PCR that there is no direct correlation between the 4R/3R ratio and tau pathology in AD patients [73-75]. On the other hand, Glatz et al. [76] demonstrated that in the temporal cortex of many AD brains, production of 4R-tau is significantly elevated, suggesting the importance of exon 10 inclusion/exclusion in the pathogenesis of AD. Nevertheless, although mutations have only been identified in the tau gene from FTDP-17 patients, tau polymorphisms, or other factors that may affect tau splicing, appear to be genetic risk factors for neurodegenerative diseases with tauopathy, in particular in PSP and AD patients.
###end p 17
###begin title 18
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
Pharmacological intervention of tau splicing in tauopathy
###end title 18
###begin p 19
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 498 502 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Tau is hyperphosphorylated and forms aggregates in brains of tauopathic patients. One would expect that small molecules and drugs that prevent these processes could be identified and used as therapeutic treatments. Not surprisingly, extensive efforts have been made to identify these molecules to inhibit formation of tau filaments or tau hyperphosphorylation as the mainstream objective in the search for drugs for treatment of tauopathies [55,77]. However, the overlooked exon 10 splicing of the tau gene has been gaining ground during the past few years as an area of study for potential treatment of tauopathies.
###end p 19
###begin p 20
###xml 162 169 162 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 272 279 272 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 544 548 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMN </italic>
###xml 552 558 552 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-x </italic>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 805 810 805 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 857 862 857 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 880 882 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
###xml 1099 1104 1099 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 1169 1171 1169 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 1221 1226 1221 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1229 1231 1229 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 1263 1268 1263 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 1319 1324 1319 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 1462 1467 1462 1467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 1492 1501 1492 1501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1552 1556 1552 1556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 1560 1564 1560 1564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMN </italic>
###xml 1640 1642 1640 1642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 1643 1645 1643 1645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 424 427 <span type="species:ncbi:10116">rat</span>
Several well-documented technologies that target aberrant splicing of specific genes in the treatment of diseases have been discussed in a recent review by Gallo et al. [55]. Among them, antisense oligoribonucleotides have been most commonly cited. For instance, Kalbfuss et al. [78] demonstrated that oligoribonucleotides binding to E10 splicing junctions could suppress the predominant inclusion of exon 10 in tau mRNA in rat PC12 cells. Other examples of modulating alternative splicing with antisense oligoribonucleotides include the genes SMN and Bcl-x [21,79]. Another strategy that is often employed to stimulate the inclusion or exclusion of a specific exon is to use bifunctional oligoribonucleotides. These molecules are made of an antisense sequence designed to bind to an exonic element and a trans-factor sequence or peptide domain mimicking a trans-splicing factor [80-82]. Relative to antisense oligonuribonucleotides or bifunctional oligoribonucleotides, spliceosome-mediated RNA trans-splicing (SMaRT) is new. SMaRT is a technology that was developed based on the natural occurring trans-splicing event between two independently transcribed pre-mRNAs [83]. By taking advantage of this finding, Puttaraju et al. [83] developed a series of RNA pre-trans-splicing molecules capable of base-pairing to and trans-splicing with a conventional target pre-mRNA. They demonstrated that splicing of the conventional pre-mRNA was modified by these RNA pre-trans-splicing molecules both in vitro and in transfected cells. SMaRT has been tested in tau and SMN and shown great promise in correcting abnormal splicing of these two genes [83-85].
###end p 20
###begin p 21
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMN1 </italic>
###xml 353 357 353 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMN2</italic>
###xml 378 383 378 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMN1 </italic>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 565 570 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMN2 </italic>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 1047 1049 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B90">90</xref>
###xml 1148 1153 1148 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMN2 </italic>
###xml 1319 1324 1319 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-x</italic>
###xml 1326 1330 1326 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 1350 1352 1350 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 1433 1438 1433 1438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMN2 </italic>
###xml 1444 1446 1444 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 1481 1485 1481 1485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMN </italic>
###xml 515 523 <span type="species:ncbi:9606">patients</span>
###xml 1236 1243 <span type="species:ncbi:9606">patient</span>
However, one specific area Gallo et al. [55] did not discuss in their review is whether small molecules or chemical compounds can potentially be used to treat diseases by targeting splicing defects. To provide proof-of-principle, we used neurodegenerative spinal muscular atrophy (SMA) as a model. SMA is caused by the homozygous loss of the SMN1 gene. SMN2, which differs from SMN1 by a single nucleotide within exon 7 that affects the efficiency of its incorporation into the mRNA transcript, is preserved in SMA patients [86,87]. Increased exon 7 insertion into SMN2 mRNA has been suggested as a potentially effective approach for SMA treatment [88]. Using a cell based assay we have developed, we identified the phosphatase inhibitor sodium orthovanadate in a small screen of chemicals known to affect signaling pathways [88]. Additional screening of a library of compounds identified aclarubicin, a chemotherapeutic anthracycline drug that is related to adriamycin [89], and indoprofen, a common non-steroidal anti-inflammatory drug (NSAID) [90]. Aclarubicin, but not adriamycin, increased the amount of full-length transcript produced by the SMN2 gene, which in turn restored SMN protein levels in fibroblasts isolated from a SMA patient. In addition, we showed that aclarubicin has no effects on the splicing of Bcl-x, tau and Myosin V genes [89], indicating a relatively specific effect of aclarubicin on the splicing of the SMN2 gene [89]. We conclude from our studies of SMN that relative specific small molecules able to reverse abnormal splicing may be identified for disease treatment.
###end p 21
###begin title 22
Conclusion
###end title 22
###begin p 23
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 260 264 260 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMN </italic>
###xml 297 301 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 782 786 782 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 957 962 957 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
Aberrant inclusion of exon 10 into tau mRNA promotes the increased production of 4R-tau and has been increasingly recognized as one of the causes of tauopathies in FTDP-17, PSP, and many AD patients [51,64-66,76]. The similarity between exon 7 splicing in the SMN gene and exon 10 splicing in the tau gene prompted us to design a cell-based assay using luciferase as a reporter for the identification of small molecules that can reverse abnormal exon 10 inclusion. The mini-reported genes are displayed in Figure 2[91]. When exon 10 is excluded, the luciferase is expressed, while inclusion of exon 10 shifts luciferase out of the reading frame, resulting in no luciferase activity. Compounds that stimulate luciferase activity would likely act by reducing exon 10 inclusion in the tau mRNA. Based on this assay, we have carried out low- and high-throughput screening. While characterizing more than 500 compounds that stimulated luciferase activity (T Zou et al., unpublished data), we speculate that it is not out of reach that relative specific small molecules will be identified for further development of drugs for treatment of tauopathies.
###end p 23
###begin p 24
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tau </italic>
###xml 114 121 114 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 128 132 128 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 479 483 479 483 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 516 524 516 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla </italic>
###xml 547 551 547 551 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
###xml 733 741 733 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla </italic>
###xml 765 769 765 769 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(D) </bold>
Validation of a cell-based luciferase system for measurement of exon 10 splicing in the tau gene (adapted from Yu et al. [91]). (A) The luciferase mini-gene construct. The firefly luciferase gene was fused downstream of exon 11 in frame with a SI9/LI10 mini-gene containing the M14 (G to T) mutation. A stop codon was introduced into exon 10 by mutagenizing position 73 in exon 10 (A to T). The nucleotide A of the initiation codon ATG in the luciferase gene was converted to T. (B) A control mini-gene with a fused Renilla luciferase to exon 11. (C) The firefly luciferase mini-gene (A) was co-transfected into SKN-MC cells with constructs of SRp40, SRp20, or SRp55. Relative firefly luciferase activities were normalized using the Renilla luciferase control (B). (D) RT-PCR from cells described in (C) was carried out to quantify exon 10 inclusion/exclusion.
###end p 24
###begin title 25
List of abbreviations used
###end title 25
###begin p 26
AD: Alzheimer's disease; ALS: amyotrophic lateral sclerosis; FTDP-17: frontotemporal dementia with Parkinsonism linked to chromosome 17; PSP: progressive supranuclear palsy; SMA: spinal muscular atrophy; SmaRT: spliceosome-mediated RNA trans-splicing; snRNP: small nuclear ribonuclear particle.
###end p 26
###begin title 27
Competing interests
###end title 27
###begin p 28
The authors declare that they have no competing interests.
###end p 28
###begin title 29
Acknowledgements
###end title 29
###begin p 30
###xml 43 60 43 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMC Neuroscience </italic>
###xml 108 111 108 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
This article has been published as part of BMC Neuroscience Volume 9 Supplement 2: 2008 Proceedings of the 8th International Conference on Alzheimer's Disease Drug Discovery The full contents of the supplement are available online at .
###end p 30
###begin article-title 31
Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology
###end article-title 31
###begin article-title 32
Alternative splicing: increasing diversity in the proteomic world
###end article-title 32
###begin article-title 33
Co-transcriptional splicing of pre-messenger RNAs: considerations for the mechanism of alternative splicing
###end article-title 33
###begin article-title 34
###xml 69 74 <span type="species:ncbi:9606">human</span>
Alternative splicing: multiple control mechanisms and involvement in human disease
###end article-title 34
###begin article-title 35
Splicing of precursors to mRNA by the spliceosome
###end article-title 35
###begin article-title 36
Construction of a novel database containing aberrant splicing mutations of mammalian genes
###end article-title 36
###begin article-title 37
A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy
###end article-title 37
###begin article-title 38
###xml 57 62 <span type="species:ncbi:9606">human</span>
The regulation of splice-site selection, and its role in human disease
###end article-title 38
###begin article-title 39
Aberrant RNA splicing in sporadic amyotrophic lateral sclerosis
###end article-title 39
###begin article-title 40
Splicing regulation in neurons: tinkering with cell-specific control
###end article-title 40
###begin article-title 41
Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis
###end article-title 41
###begin article-title 42
Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis
###end article-title 42
###begin article-title 43
The genetic and molecular mechanisms of motor neuron disease
###end article-title 43
###begin article-title 44
Splicing in disease: disruption of the splicing code and the decoding machinery
###end article-title 44
###begin article-title 45
The structure and function of proteins involved in mammalian pre-mRNA splicing
###end article-title 45
###begin article-title 46
The splicing factor BBP interacts specifically with the pre-mRNA branchpoint sequence UACUAAC
###end article-title 46
###begin article-title 47
The superfamily of arginine/serine-rich splicing factors
###end article-title 47
###begin article-title 48
###xml 15 26 15 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 15 25 <span type="species:ncbi:7227">Drosophila</span>
Binding of the Drosophila transformer and transformer-2 proteins to the regulatory elements of doublesex primary transcript for sex-specific RNA processing
###end article-title 48
###begin article-title 49
The role of specific protein-RNA and protein-protein interactions in positive and negative control of pre-mRNA splicing by Transformer 2
###end article-title 49
###begin article-title 50
A splicing enhancer complex controls alternative splicing of doublesex pre-mRNA
###end article-title 50
###begin article-title 51
Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides
###end article-title 51
###begin article-title 52
###xml 58 63 <span type="species:ncbi:9606">human</span>
Microtubule-associated protein tau gene: a risk factor in human neurodegenerative diseases
###end article-title 52
###begin article-title 53
The molecular genetics of the tauopathies
###end article-title 53
###begin article-title 54
The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer's disease
###end article-title 54
###begin article-title 55
Amyloid plaques, neurofibrillary tangles and their relevance for the study of Alzheimer's disease
###end article-title 55
###begin article-title 56
###xml 21 26 <span type="species:ncbi:9606">human</span>
Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease
###end article-title 56
###begin article-title 57
###xml 33 38 <span type="species:ncbi:9606">human</span>
Structure and novel exons of the human tau gene
###end article-title 57
###begin article-title 58
Neurodegenerative tauopathies
###end article-title 58
###begin article-title 59
Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia
###end article-title 59
###begin article-title 60
Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements
###end article-title 60
###begin article-title 61
Determinants of 4-repeat tau expression. Coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion
###end article-title 61
###begin article-title 62
Tra2 beta, SF2/ASF and SRp30c modulate the function of an exonic splicing enhancer in exon 10 of tau pre-mRNA
###end article-title 62
###begin article-title 63
Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2 beta
###end article-title 63
###begin article-title 64
Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease
###end article-title 64
###begin article-title 65
5' splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10
###end article-title 65
###begin article-title 66
Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17
###end article-title 66
###begin article-title 67
Tau exons 2 and 10, which are misregulated in neurodegenerative diseases, are partly regulated by silencers which bind a SRp30c.SRp55 complex that either recruits or antagonizes htra2beta1
###end article-title 67
###begin article-title 68
Arginine/serine-rich protein interaction domain-dependent modulation of a tau exon 10 splicing enhancer: altered interactions and mechanisms for functionally antagonistic FTDP-17 mutations Delta280K AND N279K
###end article-title 68
###begin article-title 69
Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly
###end article-title 69
###begin article-title 70
The distribution of tau in the mammalian central nervous system
###end article-title 70
###begin article-title 71
Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes
###end article-title 71
###begin article-title 72
A protein factor essential for microtubule assembly
###end article-title 72
###begin article-title 73
###xml 35 40 <span type="species:ncbi:9606">human</span>
Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization
###end article-title 73
###begin article-title 74
Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau
###end article-title 74
###begin article-title 75
The molecular parameters of tau pathology. Tau as a killer and a witness
###end article-title 75
###begin article-title 76
Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22
###end article-title 76
###begin article-title 77
Localization of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration to chromosome 17q21
###end article-title 77
###begin article-title 78
###xml 101 113 <span type="species:ncbi:9606">Participants</span>
Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants
###end article-title 78
###begin article-title 79
Hereditary dysphasic disinhibition dementia: a frontotemporal dementia linked to 17q21-22
###end article-title 79
###begin article-title 80
Chromosome 17 and hereditary dementia: linkage studies in three non- Alzheimer families and kindreds with late-onset FAD
###end article-title 80
###begin article-title 81
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17
###end article-title 81
###begin article-title 82
Tau is a candidate gene for chromosome 17 frontotemporal dementia
###end article-title 82
###begin article-title 83
Tau pathology in two Dutch families with mutations in the microtubule- binding region of tau
###end article-title 83
###begin article-title 84
Abnormal tau-containing filaments in neurodegenerative diseases
###end article-title 84
###begin article-title 85
RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies
###end article-title 85
###begin article-title 86
An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype
###end article-title 86
###begin article-title 87
Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene
###end article-title 87
###begin article-title 88
Tau gene mutation K257T causes a tauopathy similar to Pick's disease
###end article-title 88
###begin article-title 89
Pick's disease is associated with mutations in the tau gene
###end article-title 89
###begin article-title 90
Familial multiple-system tauopathy with presenile dementia is localized to chromosome 17
###end article-title 90
###begin article-title 91
FTDP-17: phenotypical heterogeneity within P301S
###end article-title 91
###begin article-title 92
FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation
###end article-title 92
###begin article-title 93
Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits
###end article-title 93
###begin article-title 94
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
###end article-title 94
###begin article-title 95
Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations
###end article-title 95
###begin article-title 96
A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto)
###end article-title 96
###begin article-title 97
FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10
###end article-title 97
###begin article-title 98
Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms
###end article-title 98
###begin article-title 99
Genetic evidence for the involvement of tau in progressive supranuclear palsy
###end article-title 99
###begin article-title 100
Clinical genetics of familial progressive supranuclear palsy
###end article-title 100
###begin article-title 101
The structure of the tau haplotype in controls and in progressive supranuclear palsy
###end article-title 101
###begin article-title 102
Association of an extended haplotype in the tau gene with progressive supranuclear palsy
###end article-title 102
###begin article-title 103
Quantitative analysis of tau isoform transcripts in sporadic tauopathies
###end article-title 103
###begin article-title 104
Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer's disease
###end article-title 104
###begin article-title 105
No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain
###end article-title 105
###begin article-title 106
The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease
###end article-title 106
###begin article-title 107
The role of tau phosphorylation and cleavage in neuronal cell death
###end article-title 107
###begin article-title 108
Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17
###end article-title 108
###begin article-title 109
Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon
###end article-title 109
###begin article-title 110
Correction of disease-associated exon skipping by synthetic exon-specific activators
###end article-title 110
###begin article-title 111
###xml 121 128 <span type="species:ncbi:9606">patient</span>
Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts
###end article-title 111
###begin article-title 112
Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides
###end article-title 112
###begin article-title 113
Spliceosome-mediated RNA trans-splicing as a tool for gene therapy
###end article-title 113
###begin article-title 114
Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies
###end article-title 114
###begin article-title 115
Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing
###end article-title 115
###begin article-title 116
The survival motor neuron protein in spinal muscular atrophy
###end article-title 116
###begin article-title 117
Identification and characterization of a spinal muscular atrophy-determining gene
###end article-title 117
###begin article-title 118
###xml 3 11 3 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
An in vivo cellular system to identify compounds that stimulate inclusion of exon 7 in SMN2 mRNA
###end article-title 118
###begin article-title 119
###xml 152 160 <span type="species:ncbi:9606">patients</span>
Identification of a compound that alters splicing of the SMN2 gene to increases full length SMN mRNA and restores gems to cells derived from type I SMA patients
###end article-title 119
###begin article-title 120
Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism
###end article-title 120
###begin article-title 121
A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10
###end article-title 121

